Prosecution Insights
Last updated: May 29, 2026

Sekisui Medical Co. Ltd.

7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
3
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (14%)
5
Medium (71%)
0
Easy (0%)
1
Unknown (14%)

Rejection Statute Mix

BucketCases
§101 only1 (14%)
§103 only4 (57%)
§102 only1 (14%)
No statute on record1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
86% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
14% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MARCETICH, ADAM M 1 72.4% +19.0%
FRITCHMAN, REBECCA M 1 45.7% +36.1%
GIERE, REBECCA M 1 73.5% +32.9%
WALLENHORST, MAUREEN 1 79.0% +5.3%
VANN-OJUEKAIYE, KENDRA RAYCHELL 1 0.0% +0.0%
GRAY, JESSICA 1 0.0% +0.0%
GAO, ASHLEY HARTMAN 1 59.8% +38.9%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17801212 METHOD FOR DETECTING TARGET NUCLEIC ACID USING DRIED BLOOD FILTER PAPER PIECE VANN-OJUEKAIYE, KENDRA RAYCHELL 53d overdue
17776741 METHOD FOR DETECTING OR QUANTIFYING OLIGONUCLEOTIDE GRAY, JESSICA 27d
17995682 METHOD FOR MEASURING BLOOD COAGULATION TIME WALLENHORST, MAUREEN 30d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17292588 METHOD FOR PREVENTING IRREGULAR DETECTION IN IMMUNOASSAY IN AUTOMATIC ANALYZER, AND IMMUNOASSAY REAGENT GAO, ASHLEY HARTMAN 78d overdue
18277424 IMMUNOLOGICAL ANALYSIS METHOD FOR TYPE-I COLLAGEN C-TERMINAL TELOPEPTIDE FRITCHMAN, REBECCA M 3d overdue
18273153 IMMUNOLOGICAL ASSAY METHOD GIERE, REBECCA M 2d overdue
18564326 BLOOD COLLECTION CONTAINER, METHOD FOR SEPARATING PLASMA, METHOD FOR SEPARATING EXTRACELLULAR FREE NUCLEIC ACID, AND METHOD FOR SEPARATING EXTRACELLULAR VESICLE MARCETICH, ADAM M 40d

Top Art Units

Art UnitApps
1682 2
3781 1
1758 1
1677 1
1797 1
1678 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18564326 BLOOD COLLECTION CONTAINER, METHOD FOR SEPARATING PLASMA, METHOD FOR SEPARATING EXTRACELLULAR FREE NUCLEIC ACID, AND METHOD FOR SEPARATING EXTRACELLULAR VESICLE MARCETICH, ADAM M 3781 §103 Final Rejection 40d Pending Nov 27, 2023
18277424 IMMUNOLOGICAL ANALYSIS METHOD FOR TYPE-I COLLAGEN C-TERMINAL TELOPEPTIDE FRITCHMAN, REBECCA M 1758 §103 Non-Final OA 3d overdue Pending Aug 16, 2023
18273153 IMMUNOLOGICAL ASSAY METHOD GIERE, REBECCA M 1677 §102 Non-Final OA 2d overdue Pending Jul 19, 2023
17995682 METHOD FOR MEASURING BLOOD COAGULATION TIME WALLENHORST, MAUREEN 1797 §101 Final Rejection 30d Pending Oct 06, 2022
17801212 METHOD FOR DETECTING TARGET NUCLEIC ACID USING DRIED BLOOD FILTER PAPER PIECE VANN-OJUEKAIYE, KENDRA RAYCHELL 1682 §103 Final Rejection 53d overdue Pending Aug 19, 2022
17776741 METHOD FOR DETECTING OR QUANTIFYING OLIGONUCLEOTIDE GRAY, JESSICA 1682 Other Final Rejection 27d Pending May 13, 2022
17292588 METHOD FOR PREVENTING IRREGULAR DETECTION IN IMMUNOASSAY IN AUTOMATIC ANALYZER, AND IMMUNOASSAY REAGENT GAO, ASHLEY HARTMAN 1678 §103 Non-Final OA 78d overdue Pending May 10, 2021

Managing Sekisui Medical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month